...
首页> 外文期刊>International Journal of Experimental Diabetes Research: Experimental Diabesity Research >Mouse Umbilical Cord Mesenchymal Stem Cell Paracrine Alleviates Renal Fibrosis in Diabetic Nephropathy by Reducing Myofibroblast Transdifferentiation and Cell Proliferation and Upregulating MMPs in Mesangial Cells
【24h】

Mouse Umbilical Cord Mesenchymal Stem Cell Paracrine Alleviates Renal Fibrosis in Diabetic Nephropathy by Reducing Myofibroblast Transdifferentiation and Cell Proliferation and Upregulating MMPs in Mesangial Cells

机译:小鼠脐带间充质干细胞通过减少肌纤维细胞转移细胞和细胞增殖和上调MMP来减轻糖尿病肾病中糖尿病肾病中的肾纤维化

获取原文
           

摘要

Transplantation of umbilical cord mesenchymal stem cells (UC-MSCs) is currently considered a novel therapeutic strategy for diabetic nephropathy (DN). However, the mechanisms by which UC-MSCs ameliorate renal fibrosis in DN are not well understood. Herein, we firstly investigated the therapeutic effects of mouse UC-MSC infusion on kidney structural and functional impairment in streptozotocin- (STZ-) induced diabetic mice. We found that the repeated injection with mUC-MSCs alleviates albuminuria, glomerulus injury, and fibrosis in DN mouse models. Next, mesangial cells were exposed to 5.6 mM glucose, 30 mM glucose, or mUC-MSC-conditioned medium, and then we performed western blotting, immunofluorescence, wound healing assay, and cell proliferation assay to measure extracellular matrix (ECM) proteins and matrix metalloproteinases (MMPs), myofibroblast transdifferentiation (MFT), and cell proliferation. We demonstrated that mUC-MSC paracrine decreased the deposition of fibronectin and collagen I by inhibiting TGF-β1-triggered MFT and cell proliferation mediated by PI3K/Akt and MAPK signaling pathways, and elevating the levels of MMP2 and MMP9. Importantly, we provided evidence that the antifibrosis role of mUC-MSC paracrine in DN might be determined by exosomes shed by MSCs. Together, these findings reveal the mechanisms underlying the therapeutic effects of UC-MSCs on renal fibrosis in DN and provide the evidence for DN cell-free therapy based on UC-MSCs in the future.
机译:脐带间充质干细胞(UC-MSCs)的移植目前被认为是一种新的糖尿病肾病(DN)治疗策略。然而,UC-MSCs在DN中改善肾纤维化的机制尚不清楚。在此,我们首先研究了小鼠UC-MSC输注对链脲佐菌素(STZ-)诱导的糖尿病小鼠肾结构和功能损伤对肾脏结构和功能损伤的治疗作用。我们发现,反复注射用MUC-MSCs缓解了DN小鼠模型中的白蛋白尿,肾小球损伤和纤维化。接下来,将Mesangial细胞暴露于5.6  mm葡萄糖,30  mm葡萄糖,或muc-msc条件培养基,然后我们进行了蛋白质印迹,免疫荧光,伤口愈合测定和细胞增殖测定以测量细胞外基质(ECM)蛋白质和基质金属蛋白酶(MMPS),肌纤维细胞转移转移(MFT)和细胞增殖。我们证明MUC-MSC旁静脉通过抑制由PI3K / AKT和MAPK信号传导途径介导的1-触发的MFT和细胞增殖,并升高MMP2和MMP9的水平,降低了纤维连接蛋白和胶原I的沉积.1-触发的MFT和细胞增殖。重要的是,我们提供了证据表明,MUC-MSC旁静脉在DN中的抗纤维抗性作用可能由MSC脱落的外索物质确定。这些研究结果在一起揭示了UC-MSCs在DN中肾纤维化对肾纤维化的治疗作用的机制,并为未来UC-MSCS提供了基于UC-MSC的无DN细胞疗法的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号